By Chris Frew | Based on the July 28, 2025 Stifel Biopharma Market Update. All quotes and data are directly attributed to that email report.
Every week I read Tim Opler’s Stifel Biopharma Market Update. This weekly email publication unpacks the Biotech investment landscape and crafts a clear narrative around the dynamic global market conditions as skillfully as that of a surgeon.
Like many of you, I’ve been riding the rollercoaster of nearly four years of headwinds, investor skepticism, and a sluggish recovery post-COVID boom. Now, according to Opler, there’s growing momentum—and evidence—that biotech’s next golden era could be taking shape. But this time, it’s arriving with a twist: the resurgence may not be led by the U.S.
According to this week’s Stifel Biopharma Market Update, “biotech is coming back big, but be vigilant as the waters ahead will be turbulent.” While the U.S.-centric XBI index has remained flat year-to-date, the global biotech landscape tells a different story.
“In aggregate, biotech is up 32% this year. It’s been a great year. Biotech is back. Just not in the U.S.,” the report notes.
China’s biotech sector has surged 122% since January, South Korea is up 40%, and Europe has posted a 16% gain. In contrast, U.S. biotech valuations are virtually unchanged—up less than 1%. The share of global biotech market cap attributed to U.S.-domiciled companies has fallen from 62% at the start of the year to just over 50%, marking a historic shift in industry dominance.
I can attribute first hand how this trend is playing out in the workforce. Other countries are taking advantage of the moment we’re in and actively recruiting away our greatest asset – our people. I’ve been approached by several overseas firms this year to help them recruit US Scientists and CMC experts for one and two year employment contracts. We’ll unpack that in a separate article.
What’s Holding U.S. Biotech Back?
Two primary challenges loom large: political uncertainty and a thinning pool of specialist investors.
First, U.S. biotech continues to face uncertainty tied to policy signals from the Trump Administration, including on MFN (Most Favored Nation) drug pricing proposals and pharmaceutical tariffs. Though recent statements have been “relatively benign,” lingering concern has kept generalist and retail investors on the sidelines.
Second, institutional capital flows have dried up. U.S. biotech is disproportionately funded by specialist mutual funds and hedge funds, and many of their limited partners have been pulling money out since early 2024. According to Lipper fund flow data, net outflows persisted from April until just last week—the first sign of reversal.
Still, sparks of optimism are surfacing. Recent acquisitions like Sanofi’s $1.6 billion purchase of France’s ViceBio and positive developments at companies like Abivax have injected new life into the sector. And while U.S. public markets have lagged, the fundamentals remain strong—and compelling.
The Fundamentals Point North
Stifel’s bullish stance is rooted in long-term demand drivers: wealth and longevity. As global wealth grows—particularly in emerging markets—and lifespans extend, demand for pharmaceuticals is expected to climb accordingly.
“Once you can survive, it becomes time to thrive and that calls for being healthy,” the report notes. “The fraction of incomes that Americans spend on healthcare has grown fourfold over the last century. We expect this growth to continue.”
The increasing longevity of the population, where individuals are living long enough to encounter more chronic diseases, ensures that pharmaceutical demand won’t plateau anytime soon. This is even more true outside the U.S., where per capita incomes in countries like India and China are rising rapidly, fueling a faster increase in drug spending.
Combine that with an accelerating pace of FDA approvals and a thriving innovation pipeline, and the argument for biotech’s long-term value proposition becomes hard to ignore.
M&A: Confidence Builder or Capital Recycler?
Mergers and acquisitions continue to be a hot topic for sector watchers. So far in 2025, Stifel reports that $1B+ biopharma deals are on pace to hit near-record levels, with expectations that the second half of the year will bring even more activity.
“M&A can build confidence in the sector and… recycle capital back,” the report states, while also cautioning that the most durable driver of value remains innovation itself. “If a company can create a drug for a price that is much less than society is willing to pay… then value has been created.”
That said, consolidation may also tighten the sector, driving greater concentration of capital into fewer, more proven entities, while early-stage ventures may still struggle to attract non-specialist dollars.
So What Will Bring Generalist Investors Back?
This is the trillion-dollar question.
Historical biotech bull runs—such as the Human Genome Project era (2000), the COVID mRNA boom (2020–21), and the high-priced specialty therapeutics wave (2012–2017)—were all driven by generalist and retail enthusiasm. Today, the same kind of seismic catalyst is needed.
Stifel outlines four major developments that could reignite broad investor interest:
- Obesity Drugs: Forecast to top $100 billion in global sales by 2028 or 2029, the next generation of obesity medications may catalyze a new investor gold rush.
- Next-Wave Oncology: From ADCs to T-cell engagers, and the promise of pan-tumor therapeutics, oncology remains ripe for breakthroughs that could capture public imagination.
- Cell Therapies as Cures: Companies like Cabaletta, Kyverna, and Immix are eliminating autoimmune diseases—and potentially curing Parkinson’s. These advances could be transformative.
- Anti-Aging Pharmaceuticals: Stifel calls this the “single most likely thing that could light the biopharma sector on fire.” The first credible lifespan-extending drug, even in animals, could shift biotech back into the investment spotlight.
“Success in this category strikes us as the single most likely thing that could light the biopharma sector on fire. The company that proves it can extend lifespan is likely to be well positioned to challenge Nvidia for today’s value creation crown,” the report boldly asserts.
Beyond the Farm Team: Building the Next “BigCo”
Traditionally, biotech has been viewed as the major leagues’ “farm team”—an early-stage innovation pipeline for big pharma to eventually buy up and scale. But that narrative is changing fast.
“We are increasingly seeing teams that are gunning to become a big pharma from day one,” the report highlights, pointing to leaders like Will Lewis at Insmed, Roger Perlmutter at Eikon, and Ron Renaud at Kailera.
The evolution of contract research and manufacturing organizations (CROs and CDMOs), as well as outsourced commercial platforms, has leveled the playing field. Today, lean, globally-networked biotechs can replicate what took big pharma decades to build.
The Global Contest for Value
Finally, there’s the broader strategic shift: biotech is becoming a more contestable industry—not just from the inside by new leadership and business models, but from the outside by countries like China, which are scaling cost-effective innovation engines with increasing speed.
“The recent growth of the Chinese biotech ecosystem serves to illustrate this vulnerability,” the report notes. “Companies have arisen that can create drugs at a lower cost, get those drugs to patients more rapidly and run clinical trials (in China at least) at high speed and reasonable cost.”
With value increasingly migrating to new business models and new geographies, U.S. biotech must adapt or risk losing its leadership position.
Final Word: Biotech’s Rebound Is Inevitable—But It Won’t Look the Same
The signs of resurgence are real. M&A is humming. Fundamentals are intact. Innovation is accelerating. And capital is starting to trickle back in. But the next boom in biotech won’t be a simple repeat of the past.
It will be global. It will be led by new players, new technologies, and new visions for how healthcare is delivered—and who delivers it.
Biotech will come back big. Just don’t expect it to look the same.
Source: July 2025 Stifel Biopharma Market Update. All quotes and data are directly attributed to that report.
